An open-label, parallel-group Phase I study to assess safety, tolerability, and pharmacokinetics of single doses of EU-C-001 administered with an apomorphine challenge, or when 90 mg EU-C-001 are administered alone BID for 7 doses in 12-hour intervals

Trial Profile

An open-label, parallel-group Phase I study to assess safety, tolerability, and pharmacokinetics of single doses of EU-C-001 administered with an apomorphine challenge, or when 90 mg EU-C-001 are administered alone BID for 7 doses in 12-hour intervals

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs EU-C 001 (Primary) ; Apomorphine
  • Indications Brain injuries; Craniocerebral trauma
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors PresSura Neuro
  • Most Recent Events

    • 06 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top